share_log

RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $179 Price Target

Benzinga ·  Dec 10 22:46  · Ratings

RBC Capital analyst Gregory Renza reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and maintains $179 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment